Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Meprednisone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 6/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.70 |
| ▸ | PGR | P06401 | 5/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.70 |
| ▸ | LMNA | P02545 | 3/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.70 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.70 |
| ▸ | FNTA | P49354 | 1/20 | 0.57 |
| ▸ | FNTB | P49356 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.55 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.55 |
| ▸ | RELA | Q04206 | 2/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.54 |
| ▸ | AR | P10275 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Meprednisone SCHEMBL20856991 | 1.00 | HSD17B10 (0.70) | HSD17B10NR3C1HIF1APGRKMT2A | |
| Meprednisone SCHEMBL5483442 | 1.00 | HSD17B10 (0.70) | HSD17B10NR3C1HIF1APGRKMT2A | |
| Meprednisone SCHEMBL19327148 | 1.00 | HSD17B10 (0.70) | HSD17B10NR3C1HIF1APGRKMT2A | |
| Meprednisone SCHEMBL11846862 | 1.00 | HSD17B10 (0.70) | HSD17B10NR3C1HIF1APGRKMT2A | |
| Meprednisone SCHEMBL16759699 | 0.93 | HSD17B10 (0.83) | HSD17B10NR3C1HIF1APGRKMT2A | |
| SCHEMBL25932838 | 0.91 | NR3C1 (0.60) | HSD17B10NR3C1HIF1APGRKMT2A | |
| SCHEMBL7611011 | 0.89 | FNTA (0.60) | HSD17B10NR3C1HIF1APGRKMT2A | |
| SCHEMBL11038018 | 0.88 | KMT2A (0.72) | HSD17B10NR3C1HIF1APGRKMT2A | |
| SCHEMBL11038901 | 0.88 | KMT2A (0.72) | HSD17B10NR3C1HIF1APGRKMT2A | |
| SCHEMBL11038015 | 0.88 | KMT2A (0.72) | HSD17B10NR3C1HIF1APGRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 11546 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139030-A1 | CHIMERIC PROTEINS FOR TREATING CUTANEOUS INFLAMMATION | SHATTUCK LABS INC (US) | 2026-05-21 | — | — | US | claimed |
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | TRAILHEAD BIOSYSTEMS INC (US) | 2026-05-07 | — | — | US | claimed |
| US-20260103492-A1 | CYCLOSPORINE COMPOSITIONS AND METHODS OF USE | BACAINN BIOTHERAPEUTICS, LTD. (KY) | 2026-04-16 | — | — | US | claimed |
| EP-4301343-B1 | PHARMACEUTICAL COMPOSITIONS WITH REDUCED SIDE EFFECT AND METHODS OF USING THE SAME | TLC BIOPHARMACEUTICALS INC (US) | 2025-11-19 | — | — | EP | claimed |
| US-12421281-B2 | Cyclosporine compositions and methods of use | BACAINN BIOTHERAPEUTICS, LTD. (KY) | 2025-09-23 | — | — | US | claimed |
| US-20250255781-A1 | PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-08-14 | — | — | US | claimed |
| WO-2025123147-A1 | TOLERIZING IMMUNOMODULATORY COMBINATION | INTEGRATED NANOTHERAPEUTICS INC. (CA) | 2025-06-19 | — | — | WO | claimed |
| EP-4567037-A1 | USE OF PYRROLOPYRIMIDINE COMPOUND IN TREATMENT OF ACUTE GRAFT VERSUS HOST DISEASE | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2025-06-11 | — | — | EP | claimed |
| US-20250179121-A1 | CYCLOSPORINE COMPOSITIONS AND METHODS OF USE | BACAINN BIOTHERAPEUTICS, LTD. (KY) | 2025-06-05 | — | — | US | claimed |
| US-4540564-A | DIHYDROPYRIDINE AND/OR PYRIDINIUM SALT REDOX CARRIER | UNIVERSITY OF FLORIDA (US) | 1985-09-10 | — | — | US | claimed |
| US-4478818-A | Ocular preparation housing steroid in two different therapeutic forms | ALZA CORPORATION (US) | 1984-10-23 | — | — | US | claimed |
| EP-0110955-A1 | BRAIN-SPECIFIC DRUG DELIVERY. | UNIV FLORIDA (US) | 1984-06-20 | — | — | EP | claimed |
| WO-1983003968-A1 | BRAIN-SPECIFIC DRUG DELIVERY | UNIVERSITY OF FLORIDA (US) | 1983-11-24 | — | — | WO | claimed |
| US-4376767-A | ANTIBIOTICS AND PHARMACEUTICALS | MERCK & CO., INC. (US) | 1983-03-15 | — | — | US | claimed |
| EP-0055870-A1 | Pyridylmethyl esters of selected bio-affecting carboxylic acids, process for preparing and pharmaceutical composition comprising the same | MERCK & CO. INC. (US) | 1982-07-14 | — | — | EP | claimed |
| EP-0051278-A1 | Soft tertiary amine esters of bio-affecting carboxylic acids, processes for preparing and a pharmaceutical composition containing the same | MERCK & CO. INC. (US) | 1982-05-12 | — | — | EP | claimed |
| US-4312865-A | Medication having penetration through cutaneous surfaces into articular and muscular areas | SZUCS MURRILL M | 1982-01-26 | — | — | US | claimed |
| US-4221787-A | Esteramide prodrugs of anti-inflammatory corticosteroids | INTERX RESEARCH CORPORATION (US) | 1980-09-09 | — | — | US | claimed |
| US-4041055-A | SULFENYLATION, MICHAEL ADDITION, REACTION WITH THIOPHILE, HYDROLYSIS | THE UPJOHN COMPANY (US) | 1977-08-09 | — | — | US | claimed |